Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells

Biochemical and Biophysical Research Communications

Volumn 439, Issue 2, 2013, Pages 179-186

  Li, Xiucheng ^a   Huang, Tao ^a   Jiang, Guangjian ^b   Gong, Weihua ^b   Qian, Hao ^a   Zou, Chunping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Invasion; MG132; Osteosarcoma; TRAIL

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GELATINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL SHAPE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; OSTEOSARCOMA; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR INVASION;

APOPTOSIS; INVASION; MG132; OSTEOSARCOMA; TRAIL;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; CASPASE 3; CASPASE 8; CELL CYCLE; CELL LINE, TUMOR; DRUG SYNERGISM; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LEUPEPTINS; M PHASE CELL CYCLE CHECKPOINTS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROTEASOME INHIBITORS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84884282286     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.066     Document Type: Article

References (36)

1. Rasalkar D.D., Chu W.C., Lee V., Paunipagar B.K., Cheng F.W., Li C.K. Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival. Pediatr. Radiol. 2011, 41:227-236.
2. Choeyprasert W., Natesirinilkul R., Charoenkwan P., Sittipreechacharn S. Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the northern region of Thailand. Asian Pac. J. Cancer Prev. 2013, 14:1101-1106.
3. Bacci G., Balladelli A., Palmerini E., Alberghini M., Pollastri P., Galletti S., Mercuri M., Picci P. Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience. J. Pediatr. Hematol. Oncol. 2008, 30:908-912.
4. Bacci G., Ferrari S., Mercuri M., Longhi A., Fabbri N., Galletti S., Forni C., Balladelli A., Serra M., Picci P. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop. 2007, 78:377-384.
5. Yang R., Sowers R., Mazza B., Healey J.H., Huvos A., Grier H., Bernstein M., Beardsley G.P., Krailo M.D., Devidas M., Bertino J.R., Meyers P.A., Gorlick R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin. Cancer Res. 2003, 9:837-844.
6. Cole P.D., Smith A.K., Kamen B.A. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother. Pharmacol. 2002, 50:111-116.
7. Guo W., Healey J.H., Meyers P.A., Ladanyi M., Huvos A.G., Bertino J.R., Gorlick R. Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res. 1999, 5:621-627.
8. Sun J., Fu Z.M., Fang C.Q., Li J.H. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents. Chin. Med. J. (Engl.) 2007, 120:400-404.
9. Chen K., Cheng H.H., Zhou R.J. Molecular mechanisms and functions of autophagy and the ubiquitin-proteasome pathway. Yi Chuan 2012, 34:5-18.
10. Meiners S., Laule M., Rother W., Guenther C., Prauka I., Muschick P., Baumann G., Kloetzel P.M., Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002, 105:483-489.
11. Koschny R., Holland H., Sykora J., Erdal H., Krupp W., Bauer M., Bockmuehl U., Ahnert P., Meixensberger J., Stremmel W., Walczak H., Ganten T.M. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. J. Neurooncol. 2010, 97:171-185.
12. Popat R., Plesner T., Davies F., Cook G., Cook M., Elliott P., Jacobson E., Gumbleton T., Oakervee H., Cavenagh J. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haematol. 2013, 160:714-717.
13. Wessel D., Flugge U.I. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem. 1984, 138:141-143.
14. Moon M.H., Jeong J.K., Seo J.S., Seol J.W., Lee Y.J., Xue M., Jackson C.J., Park S.Y. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp. Mol. Med. 2011, 43:138-145.
15. Ursini-Siegel J., Zhang W., Altmeyer A., Hatada E.N., Do R.K., Yagita H., Chen-Kiang S. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J. Immunol. 2002, 169:5505-5513.
16. Mitsiades C.S., Treon S.P., Mitsiades N., Shima Y., Richardson P., Schlossman R., Hideshima T., Anderson K.C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001, 98:795-804.
17. Locklin R.M., Federici E., Espina B., Hulley P.A., Russell R.G., Edwards C.M. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol. Cancer Ther. 2007, 6:3219-3228.
18. Szliszka E., Jaworska D., Ksek M., Czuba Z.P., Krol W. Targeting death receptor TRAIL-R2 by chalcones for trail-induced apoptosis in cancer cells. Int. J. Mol. Sci. 2012, 13:15343-15359.
19. Fossati S., Ghiso J., Rostagno A. TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Abeta. Cell Death Dis. 2012, 3:e321.
20. Jiang J. Regulation of Hh/Gli signaling by dual ubiquitin pathways. Cell Cycle 2006, 5:2457-2463.
21. Kinyamu H.K., Chen J., Archer T.K. Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors. J. Mol. Endocrinol. 2005, 34:281-297.
22. Milacic V., Banerjee S., Landis-Piwowar K.R., Sarkar F.H., Majumdar A.P., Dou Q.P. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008, 68:7283-7292.
23. Almond J.B., Cohen G.M. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002, 16:433-443.
24. Mutlu A., Gyulkhandanyan A.V., Freedman J., Leytin V. Activation of caspases-9, -3 and -8 in human platelets triggered by BH3-only mimetic ABT-737 and calcium ionophore A23187: caspase-8 is activated via bypass of the death receptors. Br. J. Haematol. 2012, 159:565-571.
25. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 1999, 15:269-290.
26. Rastogi N., Mishra D.P. Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div. 2012, 7:26.
27. Landis-Piwowar K.R. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem. Clin. Lab. Sci. 2012, 25:38-44.
28. Demasi M., Laurindo F.R. Physiological and pathological role of the ubiquitin-proteasome system in the vascular smooth muscle cell. Cardiovasc. Res. 2012, 95:183-193.
29. Wong V.K., Cheung S.S., Li T., Jiang Z.H., Wang J.R., Dong H., Yi X.Q., Zhou H., Liu L. Asian ginseng extract inhibits in vitro and in vivo growth of mouse lewis lung carcinoma via modulation of ERK-p53 and NF-kappaB signaling. J. Cell. Biochem. 2010, 111:899-910.
30. Ji L., Chen Y., Liu T., Wang Z. Involvement of Bcl-xL degradation and mitochondrial-mediated apoptotic pathway in pyrrolizidine alkaloids-induced apoptosis in hepatocytes. Toxicol. Appl. Pharmacol. 2008, 231:393-400.
31. Yang H., Chen D., Cui Q.C., Yuan X., Dou Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66:4758-4765.
32. An B., Goldfarb R.H., Siman R., Dou Q.P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998, 5:1062-1075.
33. Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997, 15:2991-2997.
34. Katayose Y., Kim M., Rakkar A.N., Li Z., Cowan K.H., Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 1997, 57:5441-5445.
35. Gerspach J., Pfizenmaier K., Wajant H. Therapeutic targeting of CD95 and the TRAIL death receptors. Recent Pat. Anticancer Drug Discov. 2011, 6:294-310.
36. Zanchi C., Zuco V., Lanzi C., Supino R., Zunino F. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer Res. 2005, 65:2364-2372.